Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

PANORAMA Helps Regeneron's Eylea Even Score With Roche's Lucentis

Mar 20 2018

• By Emily Hayes

Render illustration of Clinical Trial title on medical documents

Related Content

Keeping Track: US FDA Expands Indications For Roche Tecentriq, Lucentis, Approves Second Infliximab Biosimilar

Apr 24 2017

Keeping An Eye On Regeneron: What's Next To Drive Growth

Nov 08 2017

Keeping Track: New Indication For Lucentis; New Lesinurad Application From Ironwood

Jan 06 2017

As Regeneron Worries Rise On Eylea Combo Failure, Eyes Turn To PANORAMA

Nov 27 2017

Related Companies

Regeneron Pharmaceuticals, Inc.

Novartis AG

Bayer AG

Roche Holding AG

Additional Topics

Clinical Trials Market Intelligence Research & Development Ophthalmic BioPharmaceutical

More from Sensory

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window